Novo Nordisk stops two more ziltivekimab heart trials, HERMES and ATHENA, after July's ZEUS failure casts doubt on IL-6 inhibition in heart disease.

Novo Nordisk stops two more ziltivekimab heart trials, HERMES and ATHENA, after July's ZEUS failure casts doubt on IL-6 inhibition in heart disease.

Earlier this year, Novo said ziltivekimab failed to reduce the risk of heart attacks and strokes, diminishing expectations for other ongoing studies.